FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804571292> ?p ?o ?g. }

• W2804571292 endingPage "1680" @default.
• W2804571292 startingPage "1670" @default.
• W2804571292 abstract "Apatinib, a small-molecule inhibitor of VEGFR-2, has attracted much attention due to its encouraging anticancer activity in third-line clinical treatment for many malignancies, including non-small cell lung cancer (NSCLC). Its usage in second-line therapy with chemotherapeutic drugs is still under exploration. In this study we investigated the antitumor effect of apatinib combined with docetaxel against NSCLC and its cellular pharmacokinetic basis. A549 xenograft nude mice were treated with apatinib (100 mg/kg every day for 20 days) combined with docetaxel (8 mg/kg, ip, every four days for 5 times). Apatinib significantly enhanced the antitumor effect of docetaxel and alleviated docetaxel-induced liver damage as well as decreased serum transaminases (ALT and AST). LC-MS/MS analysis revealed that apatinib treatment significantly increased the docetaxel concentration in tumors (up to 1.77 times) without enhancing the docetaxel concentration in the serum, heart, liver, lung and kidney. Furthermore, apatinib decreased docetaxel-induced upregulation of P-glycoprotein in tumors. The effects of apatinib on the uptake, efflux and subcellular distribution of docetaxel were investigated in A549 and A549/DTX (docetaxel-resistant) cells in vitro. A cellular pharmacokinetic study revealed that apatinib significantly increased cellular/subcellular accumulation (especially in the cytosol) and decreased the efflux of docetaxel in A549/DTX cells through P-gp, while apatinib exerted no significant effect on the cellular pharmacokinetics of docetaxel in A549 cells. Consequently, the IC50 value of docetaxel in A549/DTX cells was more significantly decreased by apatinib than that in A549 cells. These results demonstrate that apatinib has potential for application in second-line therapy combined with docetaxel for NSCLC patients, especially for docetaxel-resistant or multidrug-resistant patients." @default.
• W2804571292 created "2018-06-01" @default.
• W2804571292 creator A5004836644 @default.
• W2804571292 creator A5009021677 @default.
• W2804571292 creator A5011573172 @default.
• W2804571292 creator A5014455930 @default.
• W2804571292 creator A5018863416 @default.
• W2804571292 creator A5027621774 @default.
• W2804571292 creator A5050810233 @default.
• W2804571292 creator A5061680211 @default.
• W2804571292 creator A5071878141 @default.
• W2804571292 creator A5086958208 @default.
• W2804571292 date "2018-05-17" @default.
• W2804571292 modified "2023-10-17" @default.
• W2804571292 title "Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis" @default.
• W2804571292 cites W1571571100 @default.
• W2804571292 cites W1813937895 @default.
• W2804571292 cites W1967600348 @default.
• W2804571292 cites W1981186476 @default.
• W2804571292 cites W1988681679 @default.
• W2804571292 cites W2021634801 @default.
• W2804571292 cites W2035183057 @default.
• W2804571292 cites W2055192249 @default.
• W2804571292 cites W2056163905 @default.
• W2804571292 cites W2069907205 @default.
• W2804571292 cites W2071244202 @default.
• W2804571292 cites W2079150103 @default.
• W2804571292 cites W2096523159 @default.
• W2804571292 cites W2096795721 @default.
• W2804571292 cites W2098064809 @default.
• W2804571292 cites W2102590541 @default.
• W2804571292 cites W2105464202 @default.
• W2804571292 cites W2105968397 @default.
• W2804571292 cites W2112524831 @default.
• W2804571292 cites W2115078104 @default.
• W2804571292 cites W2115991409 @default.
• W2804571292 cites W2139526755 @default.
• W2804571292 cites W2140980839 @default.
• W2804571292 cites W2145092426 @default.
• W2804571292 cites W2157304247 @default.
• W2804571292 cites W2161000665 @default.
• W2804571292 cites W2170030318 @default.
• W2804571292 cites W2234448017 @default.
• W2804571292 cites W2331067690 @default.
• W2804571292 cites W2472305226 @default.
• W2804571292 cites W2547100318 @default.
• W2804571292 cites W2566159668 @default.
• W2804571292 cites W2580010201 @default.
• W2804571292 cites W2594982122 @default.
• W2804571292 cites W2598230851 @default.
• W2804571292 cites W2617206715 @default.
• W2804571292 cites W2766366470 @default.
• W2804571292 doi "https://doi.org/10.1038/aps.2018.16" @default.
• W2804571292 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6289402" @default.
• W2804571292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29770798" @default.
• W2804571292 hasPublicationYear "2018" @default.
• W2804571292 type Work @default.
• W2804571292 sameAs 2804571292 @default.
• W2804571292 citedByCount "17" @default.
• W2804571292 countsByYear W28045712922018 @default.
• W2804571292 countsByYear W28045712922019 @default.
• W2804571292 countsByYear W28045712922020 @default.
• W2804571292 countsByYear W28045712922021 @default.
• W2804571292 countsByYear W28045712922022 @default.
• W2804571292 crossrefType "journal-article" @default.
• W2804571292 hasAuthorship W2804571292A5004836644 @default.
• W2804571292 hasAuthorship W2804571292A5009021677 @default.
• W2804571292 hasAuthorship W2804571292A5011573172 @default.
• W2804571292 hasAuthorship W2804571292A5014455930 @default.
• W2804571292 hasAuthorship W2804571292A5018863416 @default.
• W2804571292 hasAuthorship W2804571292A5027621774 @default.
• W2804571292 hasAuthorship W2804571292A5050810233 @default.
• W2804571292 hasAuthorship W2804571292A5061680211 @default.
• W2804571292 hasAuthorship W2804571292A5071878141 @default.
• W2804571292 hasAuthorship W2804571292A5086958208 @default.
• W2804571292 hasBestOaLocation W28045712921 @default.
• W2804571292 hasConcept C112705442 @default.
• W2804571292 hasConcept C126322002 @default.
• W2804571292 hasConcept C185592680 @default.
• W2804571292 hasConcept C2776256026 @default.
• W2804571292 hasConcept C2776694085 @default.
• W2804571292 hasConcept C2780668389 @default.
• W2804571292 hasConcept C2781190966 @default.
• W2804571292 hasConcept C502942594 @default.
• W2804571292 hasConcept C71924100 @default.
• W2804571292 hasConcept C81729549 @default.
• W2804571292 hasConcept C98274493 @default.
• W2804571292 hasConceptScore W2804571292C112705442 @default.
• W2804571292 hasConceptScore W2804571292C126322002 @default.
• W2804571292 hasConceptScore W2804571292C185592680 @default.
• W2804571292 hasConceptScore W2804571292C2776256026 @default.
• W2804571292 hasConceptScore W2804571292C2776694085 @default.
• W2804571292 hasConceptScore W2804571292C2780668389 @default.
• W2804571292 hasConceptScore W2804571292C2781190966 @default.
• W2804571292 hasConceptScore W2804571292C502942594 @default.
• W2804571292 hasConceptScore W2804571292C71924100 @default.
• W2804571292 hasConceptScore W2804571292C81729549 @default.
• W2804571292 hasConceptScore W2804571292C98274493 @default.

• next